Larimar Therapeutics, Inc. Common Stock (LRMR) is a publicly traded Healthcare sector company. As of May 21, 2026, LRMR trades at $3.53 with a market cap of $336.58M and a P/E ratio of 0.00. LRMR moved +5.71% today. Year to date, LRMR is +5.06%; over the trailing twelve months it is +71.36%. Its 52-week range spans $1.61 to $9.50. Analyst consensus is strong buy with an average price target of $16.00. Rallies surfaces LRMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Larimar Plans June Rolling BLA Submission with $200M Cash Runway: Larimar plans to initiate a rolling BLA submission for nomlabofusp in June 2026, with CMC modules due in H2 2026, and expects topline open-label study data in Q2 2026. The company held $200.4 million in cash and equivalents as of March 31, extending its runway into Q2 2027.
| Metric | Value |
|---|---|
| Price | $3.53 |
| Market Cap | $336.58M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.50 |
| 52-Week Low | $1.61 |
| Volume | 1.74M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-165.67M |
| Gross Margin | 0.00% |
5 analysts cover LRMR: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.00.